Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-02-27
2009-08-04
Robinson, Hope A (Department: 1652)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C530S300000, C530S324000, C514S008100, C514S002600
Reexamination Certificate
active
07569543
ABSTRACT:
The present invention relates to Ang-1, Ang-2, and Ang-3, and to methods and uses of the same. The present invention also relates to ECM-binding fragments, non-ECM-binding fragments, proteolytic resistant fragments and C-terminal fragments of Ang-1, and to methods and uses of the same.
REFERENCES:
patent: 6441137 (2002-08-01), Davis et al.
Folkman, “Tumor angiogenesis: therapeutic implications,” New. Eng. J. Med. (1971) 285:1182-1186.
Risau, “Mechanisms of angiogenesis,” Nature (1997) 386:671-674.
Kim, et al., “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo,” Nature (1993) 362:841-844.
Hanahan and Folkman, “Patterns and emerging mechanisms fo the angiogenic switch during tumorigenesis,” Cell (1996) 86:353-364.
Hanahan, “Signalling vascular morhogenesis and maintenance,” Science (1997) 277:48-50.
Hanahan and Weinberg, “The hallmarks of cancer,” Cell (2000) 100:57-70.
Folkman and D'Amore, “Blood vessel formation: what is its molecular basis?”, Cell (1996) 87:1153-1155.
Yancopoulos, et al., “Vascular-specific growth factors and blood vessel formation,” Nature (2000) 407:242-248.
Ingber and Folkman, “How does extracellular matrix control capillary morphogenesis?”, Cell (1989) 58:803-805.
Ramsauer and D'Amore, “Getting tie(2)d up in angiogenesis,” J. Clin. Investig. (2002) 110:1615-1617.
Betsholtz, et al., “Developmental roles of platelet-derived growth factors,” BioEssays (2001) 23:494-507.
Fong, et al., “Role of the Fit-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium,” Nature (1995) 376:66-70.
Maisonpierre, et al., “Angiopoietin-2, a natural antagonist for tie2 that disrupts in vivo angiogenesis,” Science (1997) 277:55-60.
Sato, et al., “tie-1 and tie-2 define another class of putative receptor tyrosine kinase genes expressed in early embryonic vascular system,” Proc. Natl. Acad. Sci. USA (1993) 90:9355-9358.
Schnurch and Risau, “Expression of the tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage,” Development (1993) 119:957-968.
Dumont, et al., “Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo,” Genes Dev. (1994) 8:1897-1909.
Coogan, et al., “Expression of tie2/tek in breast tumor vasculature provides a new marker for evaluation of tumor angiogenesis,” Br. J. Cancer (1998) 77:51-56.
Sato, et al., “Distinct roles of the receptor tyrosine kinases tie-1 and tie-2 in blood vessel formation,” Nature (1995) 376:70-74.
Suri, et al., “Requisite role of angiopoietin-1, a ligand for the Tie2 receptor during embryonic angiogenesis,” Cell (1996) 87:1171-1180.
Gale and Yancopoulos, “Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development,” Genes Dev. (1999) 13:1055-1066.
Suri, et al., “Increased vascularization in mice overexpressing angiopoietin-1,” Science (1998) 282:468-471.
Thurston, et al., “Leakage-resistant blood vessels in mice transenically overexpressing angiopoietin-1,” Science (1999) 286:2511-2514.
Thurston, et al., “Angiopoietin-1 protects the adult vasculature against plasma leakage,” Nature Med. (2000) 6:460-463.
Stratmann, et al., “Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis,” Am. J. Pathol. (1998) 153:1459-1468.
Witzenbichler, et al., “Chemotactic properties of angiopoietin-1 and -2, ligands for the endothelial-specific receptor tyrosine kinase tie2.,” J. Biol. Chem. (1998) 273:18514-18521.
Carlson, et al., “Direct cell adhesion to the angiopoietins mediated by integrins,” J. Biol. Chem. (2001) 276:26516-26525.
Papapetropoulos, et al., “Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway,” J. Biol. Chem. (2000) 275:9102-9105.
Kim, et al., “Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway,” Circulation Res. (2000) 86:24-29.
Hayes, et al., “Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubulin formation and survival of endothelial cells,” Microvasc. Res. (1999) 58:224-237.
Oh, et al., “Hypoxia and vascular endothelial growth factor selectively upregulate angiopoietin-2 in bovine microvascular endothelial cells,” J. Biol. Chem. (1999) 274:15732-15739.
Mandriota and Pepper, “Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia,” Circulation Res. (1998) 83:852-859.
Kim, et al., “Tumor necrosis factor-alpha upregulates angiopoietin-2 in human umbilical vein endothelial cells,” Biochem. Biophys. Res. Comm. (2000) 269:361-365.
Kim, et al., “Angiopoietin-1 induces endothelial cell sprouting through the activation of focal adhesion kinase and plasmin secretion,” Circulation Res. (2000) 86:952-959.
Valenzuela, et al., “Angiopoietins 3 and 4: diverging gene counterparts in mice and humans,” Proc. Natl. Acad. Sci. USA (1999) 96:1904-1909.
Siemeister, et al., “Two independent mechanisms essential for tumor angiogenesis: inhibition fo human melanoma xenograft growth by interfering with eiter the vascular endothelial growth factor receptor pathway of the tie-2 pathway,” Cancer Res. (1999) 59:3185-3193.
Millauer, et al., “Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant,” Nature (1994) 367:576-579.
Goldman, et al., “Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastsis, and mortality rate,” Proc. Natl. Acad. Sci. USA (1998) 95:8795-8800.
Ahmad, et al., “The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer,” Cancer Res. (2001) 61:1255-1259.
Etoh, et al., “Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma:possible in vivo regulation via induction of proteases,” Cancer Res. (2001) 61:2145-2153.
Hawighorst, et al., “Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation nad impairs squamous cell carcinoma growth,” Am. J. Pathol. (2002) 100:1381-1392.
Koga, et al., “Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis,” Cancer Res. (2001) 61:6248-6254.
Papetti and Herman, “Mechanisms of normal and tumor-derived angiogenesis,” Am. J. Physiol. Cell Physiol. (2002) 282:C947-C970.
Teichert-Kuliszewska, et al., “Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation if Tie2,” Cardiovasc. Res. (2001) 49:659-670.
Yu and Stamenkovic, “Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion,” Genes Dev. (1999) 13:35-48.
Hungerford and Little, “Developmental biology of the vascular smooth muscle cell: building a multilayed vessel wall,” J. Vasc. Res. (1999) 36:2-27.
Gale, et al., “Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1,” Devel. Cell (2002) 3:411-423.
Shyu, et al., “Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb,” Circulation (1998) 98:2081-2087.
Kim, et al., “Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3&#x
Pepper Hamilton LLP
Robinson Hope A
The Trustees of the University of Pennsylvania
LandOfFree
Compositions of Angiopoietin, fragments, mutants and analogs... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions of Angiopoietin, fragments, mutants and analogs..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions of Angiopoietin, fragments, mutants and analogs... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4100153